Skip to content
Open access

NLRX1 is an essential, druggable regulator of mitochondrial permeability transition

Aug 2026 · bioRxiv · 0 citations · 52 references
Biology

TL;DR

NLRX1 is established as an essential, CypD-independent regulator of mitochondrial permeability transition and provide brain-penetrant chemical tools to interrogate this biology.

Read PDF

Similar papers

Review Open access Aug 2026

NLRX1 emerges as the only observed essential regulator of the mPTP, challenging mPTP inhibition as a valid target of cardioprotection

It is proposed that NLRX1 is the only currently identified protein that is strictly required for mPTP opening, and that indiscriminate inhibition of the mPTP is unlikely to represent a universally effective cardioprotective strategy against I/R injury.

Kielen R. Zuurbier, C. Zuurbier · 0 citations
Aug 2026

PGAM5-mediated VDAC1 oligomerization Facilitates Ponatinib-Induced Cardiotoxicity via Disrupting the Mitophagy-Mitochondrial unfolded protein response Synergistic Defense Crosstalk.

These findings identify the PGAM5/VDAC1 axis as a key mechanism linking ponatinib stress to coordinated failure of MQC in the heart and targeting PGAM5-dependent VDAC1 oligomerization may represent a potential strategy for limiting ponatinib-associated cardiotoxicity.

Yu-Yue Li, Dandan Yuan, Haitao Zhou et al. · 0 citations
Jul 2026

Discovery of Novel Anethole Trithione Derivatives Targeting SQR Pathway to Induce Mitochondrial Uncoupling for Stroke Treatment.

Hydrogen sulfide (H2S) is an endogenous gasotransmitter with therapeutic potential for stroke. Our previous work identified that ADT-OH, an H2S donor with mitochondrial uncoupling activity, protects against stroke by activating the SQR-UCP2-AMPK pathway. Here, we launched a medicinal chemistry campaign based on hit com...

Peng Song, Yuan Li, Xiaohan Song et al. · 0 citations
Review Open access Aug 2026

Chemoproteomic discovery of a brain-penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket.

Optimization of ligands targeting Cys463 of NLRP3 within a previously uncharacterized allosteric pocket led to a unique and potent inhibitor series with attractive physicochemical and pharmacokinetic properties for the potential treatment of diseases involving aberrant innate immune activation in both central and perip...

Donald C. Rogness, E. Sievert, Vincent F Vartabedian et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.